Scholar Rock’s Quiet Descent

In the second quarter, Scholar Rock stood where many young biotechs find themselves: adrift between ambition and reality. There were no revenues to speak of, only losses-losses so vast they seemed almost theatrical. The net loss for the period reached over $110 million, or $0.98 per share, a figure far grimmer than the nearly $59 million deficit from the same quarter last year. Analysts, those cautious prophets of Wall Street, had braced themselves for bad news-but not this bad. Their consensus estimate anticipated a shortfall of just $0.66 per share.








